This has potential relevance in the treatment of glaucoma, a major eye disease. In another animal model, substantial re-growth of axons in the pyramidal tract of injured spinal cords was achieved. Further larger-scale in vivo results now appear to confirm that our endogenous compound is, to our knowledge, unique in its ability to regenerate both injured optic nerves and spinal cord axons to such a substantial extent. In addition to chronic diseases of the CNS, such as PD and Alzheimer's Disease, the potential markets for our agents are stroke and spinal cord injury. Within the extremely important transcription factor and gene vector technologies discovered by Professor Laurie Glimcher of Harvard University dealing with the key role that Th1 and Th2 cells play in the development of autoimmune diseases and allergies, we have identified a portfolio of partnering opportunities.
Intensive discussions are in progress.
The scope of Dr. Glimcher's elucidation of the fundamental control mechanism in immunology is truly impressive. Inc. BLSI is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders. The foregoing contains certain forward-looking statements with regard to product development, which may not be realized due to the uncertainties inherent in the research and development and regulatory processes, as well as market conditions. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include uncertainties associated with the results of human clinical trials, regulatory approval processes and other factors. The foregoing contains forward-looking statements with regard to product development, which may not be realized due to the uncertainties inherent in the research and development process, including applying laboratory results to the design and completion of clinical trials as well as the previously mentioned uncertainties.